{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:55:36Z","timestamp":1765961736029},"reference-count":14,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1097\/hs9.0000000000000968","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T15:02:49Z","timestamp":1698937369000},"page":"e968","source":"Crossref","is-referenced-by-count":4,"title":["Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001"],"prefix":"10.1002","volume":"7","author":[{"given":"Luca L.G.","family":"Janssen","sequence":"first","affiliation":[{"name":"Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresia M.","family":"Westers","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Rovers","sequence":"additional","affiliation":[{"name":"Mendus AB, R&D Center, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.M.","family":"Valk","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Cloos","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"},{"name":"Amsterdam UMC, Vrije Universiteit, Department of Medical Oncology, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan A.","family":"van de Loosdrecht","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11]]},"reference":[{"key":"R1-20231102","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS.","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"R2-20231102","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML.","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20231102","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2019-02-897579","article-title":"Maintenance therapy for AML: are we there yet?","volume":"133","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"R4-20231102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future.","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"R5-20231102","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/jcm8050579","article-title":"Dendritic cell-based Immunotherapy of acute myeloid leukemia.","volume":"8","author":"Van Acker","year":"2019","journal-title":"J Clin Med"},{"key":"R6-20231102","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.","volume":"67","author":"Van de Loosdrecht","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R7-20231102","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system.","volume":"29","author":"R\u00f6llig","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-20231102","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"R9-20231102","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"key":"R10-20231102","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission.","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"R11-20231102","doi-asserted-by":"crossref","first-page":"650473","DOI":"10.3389\/fonc.2021.650473","article-title":"Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter.","volume":"11","author":"Kordella","year":"2021","journal-title":"Front Oncol"},{"key":"R12-20231102","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","article-title":"Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.","volume":"5","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"R13-20231102","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cells10113233","article-title":"Transfer of cellular content from the allogeneic cell-based cancer vaccine DCP-001 to host dendritic cells hinges on phosphatidylserine and is enhanced by CD47 blockade.","volume":"10","author":"Zuo","year":"2021","journal-title":"Cells"},{"issue":"Supplement 1","key":"R14-20231102","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood-2022-162169","article-title":"Use of an allogeneic leukemia-derived dendritic cell vaccine in MRD+ AML-patients results in MRD conversion, improved relapse-free survival and vaccine induced immune responses to tumor antigens.","volume":"140","author":"Van de Loosdrecht","year":"2022","journal-title":"Blood"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T18:14:22Z","timestamp":1702923262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HS9.0000000000000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hs9.0000000000000968","relation":{},"ISSN":["2572-9241"],"issn-type":[{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}